SAN MATEO, CA, PrognomiQ today announced it has raised $46 million in financing round.
PrognomiQ - a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases - today announced it has raised $46 million in financing led by Bruker Corporation, with participation from new investors, including Catalio Capital Management, and from existing investors including aMoon, Fidelity Management and Research Company LLC, funds and accounts advised by T. Rowe Price Associates, Inc., Invus, Maverick Ventures, Emerson Collective and Wing VC. The closing of this round brings PrognomiQ's total funding to more than $101 million since the company was founded in September 2020.
Founded in 2020, PrognomiQ is a healthcare company pursuing the development and commercialization of multi-omics human tests for cancer and other complex diseases. PrognomIQ uses leading edge proteomics technologies, in addition to metabolomics and genomics technologies, to develop multi-omics products to improve human health.
(c) by Massinvestor, Inc. For contact info, please check out our about